

Table 1: Literature review regarding alpha fetoprotein producing esophageal adenocarcinomas.

Author (Year)	Gender	Age (years)	Histologic Subtype	Serum AFP Level (ng/ml)	Metastasis	Treatment	Survival (months)
Sawada et al. (1993)	Male	80	AFP-producing	351.5	Liver, spleen, lung, LN	Surgery, tegafur, lentinan, radiotherapy	4
Motoyama et al. (1995)	Female	80	Hepatoid	NR	Liver, lung	Bleomycin	2
Shimakawa et al. (1999)	Male	59	AFP-producing	1500	Liver, LN	Chemotherapy	2
Kobayashi et al. (2001)	Male	51	AFP-producing	52.4	Pleura, LN	Surgery, 5-FU, Cisplatin	67
Tanigawa et al. (2002)	Female	44	Hepatoid	Normal	Liver	Surgery, chemotherapy	4
Kawai et al. (2003)	Male	69	AFP-producing	76.9	NR	Surgery	6 (alive at last FU)
Chiba et al. (2005)	Male	47	Hepatoid	326400	Liver	Cisplatin, paclitaxel	14
Fukuzawa et al. (2005)	Male	55	Hepatoid	47800	Lung, bone, LN	Surgery, chemotherapy	9
Atiq et al. (2008)	Male	56	Hepatoid	>3000	Liver	NR	NR
Kuroda et al. (2011)	Male	76	Hepatoid	NR	NR	Surgery	2 (alive at last FU)
Takeyama et al. (2012)	Male	58	Hepatoid	3788	None	Surgery, S-1 chemotherapy	22 (alive at last FU)
Chen et al. (2013)	Male	45	AFP-producing	28.6	Liver, pleura, peritoneum, LN	Surgery, 5-FU, cisplatin, oxaliplatin, radiotherapy	19
Nagai et al. (2014)	Male	62	Hepatoid	NR	Liver	Surgery, cisplatin, S-1 chemotherapy	24 (alive at last FU)
Kashani et al. (2017)	Male	83	Hepatoid	>300000	Liver, lung, mediastinum, LN	None	4
Wang et al. (2017)	Male	51	AFP-producing	2524	Liver, LN	None	2
Apostolou et al. (2020)	Male	35	Hepatoid	631	Liver	Surgery, trans-arterial chemoembolization	15
Summary	16 patients M/F: 14/2 87.5% Male	Mean Age: 59.4 Males: 59.1 Females: 62	10 Hepatoid 6 AFP-producing	Median Value:1066 (10 studies)	Liver: 11, LN: 7 Lung: 4, Pleura: 2 Bone: 1, Spleen: 1 Peritoneum: 1 Mediastinum: 1	Surgery: 10 Chemotherapy: 10 Radiotherapy: 2 Trans-arterial chemoembolization: 1	Median Survival: 4 months

FU: follow-up, AFP: alpha-fetoprotein, LN: Lymph nodes, NR: Not reported, 5-FU: fluorouracil.